Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.79 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.65 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.62 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | F7 | P08709 | 1/20 | 0.55 |
| ▸ | F3 | P13726 | 1/20 | 0.55 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14110105 | 0.91 | PLOD2 (0.72) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL10320930 | 0.90 | PLOD2 (0.89) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL29554726 | 0.90 | PLOD2 (0.89) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL4625207 | 0.89 | PLOD2 (1.00) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL30440488 | 0.89 | PLOD2 (1.00) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL9466134 | 0.84 | PLOD2 (0.68) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL6611633 | 0.83 | PLOD2 (0.71) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL30489910 | 0.83 | PLOD2 (0.71) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL29450185 | 0.83 | PLOD2 (0.66) | PLOD2PLOD3PLOD1ALDH1A1APP | |
| SCHEMBL5158150 | 0.83 | PLOD2 (0.71) | PLOD2PLOD3PLOD1ALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334381-B2 | Process for the preparation of intermediates useful in the synthesis of imatinib | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-12-18 | — | — | US | claimed |
| US-20100234598-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | FALCHI ALESSANDRO | 2010-09-16 | — | — | US | claimed |
| EP-2074095-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2009-07-01 | — | — | EP | claimed |
| WO-2008059551-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2008-05-22 | — | — | WO | claimed |
| WO-2007053773-A1 | COMPOSITIONS AND METHODS USING NICOTINIC ACID FOR TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE | HENDRIX CURT (US) | 2007-05-10 | — | — | WO | claimed |
| US-20070105793-A1 | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease | CONCOURSE HEALTH SCIENCES LLC | 2007-05-10 | — | — | US | claimed |
| WO-2001014310-A1 | PLEUROMUTILIN β-KETOESTERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-03-01 | — | — | WO | claimed |
| EP-4631931-A1 | HDAC INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| CN-118772048-A | HDAC inhibitor and application thereof | 微境生物医药科技(上海)有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-107021951-A | SGC stimulators | 铁木医药有限公司 | 2017-08-08 | — | — | CN | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| CN-103313976-B | sGC stimulators | 铁木医药有限公司 | 2016-11-23 | — | — | CN | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| EP-0333080-B1 | BETA-CARBONYL-CARBOXYAMIDES OF 1,3-THIAZOLIDINES | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-10-13 | — | — | EP | disclosed |
| US-5206254-A | Antitussive agents | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-04-27 | — | — | US | disclosed |
| EP-0407403-A1 | BETA-CARBONYL-CARBOXYAMIDES OF 1,3-THIAZOLIDINES | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1991-01-16 | — | — | EP | disclosed |
| WO-1989008648-A1 | beta-CARBONYL-CARBOXYAMIDES OF 1,3-THIAZOLIDINES | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1989-09-21 | — | — | WO | disclosed |
| EP-0333080-A1 | Beta-carbonyl-carboxyamides of 1,3-thiazolidines | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
| US-4710508-A | ANALGESICS | WARNER-LAMBERT COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234598-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | ABL1, PDGFRA, ABL2 | PLOD2 3351/4885PLOD3 4322/4885PLOD1 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.